Oxford Bio's TroVax salvaged

Gene therapy specialist Oxford BioMedica said yesterday that a ruling by US regulators has cleared the way for it to develop its lead drug in a range of cancers, following a review of a failed trial. TroVax, which is being developed with Sanofi-Aventis, missed a key goal in a Phase III renal cancer trial in July last year, causing a key safety board to stop its development. But it has now acknowledged that confounding factors may have contributed to the increased number of deaths in the trial.